Table 2

Mean and SD (unweighted values) for bronchodilator responses for whole study population, healthy and COPD subgroups

VariablesStudy populationHealthy subgroupCOPD GS2+COPD GS2+ (without asthma)
AllMenWomenMen and womenMen and womenMen and women
FEV1-based measuresN1=10 217N1=4826N1=5391N1=3922N1=1009N1=745
 ΔFEV1 (ml)82 (139)95 (156)70 (120)72 (130)114 (157)104 (153)
 ΔFEV1i (%)3.7 (6.9)3.6 (6.5)3.8 (7.3)3.1 (6.0)8.8 (11.9)7.7 (11.0)
 ΔFEV1p (%)2.8 (4.8)2.7 (4.6)2.8 (5.0)2.6 (4.8)4.2 (5.7)3.7 (5.5)
FVC-based measuresN2=9546N2=4560N2=4986N2=3593N2=976N2=723
 ΔFVC (ml)0 (237)4 (257)−4 (217)−21 (219)153 (280)138 (273)
 ΔFVCi (%)0.5 (7.9)0.5 (6.9)0.5 (8.7)−0.3 (7.4)6.9 (12.2)6.2 (11.9)
 ΔFVCp (%)0.1 (6.6)0.2 (5.9)0 (7.3)−0.5 (6.7)4.4 (7.9)4.0 (7.6)
  • ΔFEV1 (ml) and ΔFVC (ml) are absolute change after bronchodilator; ΔFEV1i and ΔFVCi are change as a per cent of initial value.

  • ΔFEV1p and ΔFVCp are change as per cent of predicted value. N1 is number with non-missing FEV1 values and N2 is number with non-missing FVC values.

  • COPD GS2+ = FEV1/FVC <0.7 and FEV1% predicted<80%; COPD GS2+ (without asthma) = post-bronchodilator spirometrically defined COPD excluding those with self-reported asthma.

  • COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.